The Overweight rating from Cantor Fitzgerald indicates that the analyst believes Health Catalyst's stock will outperform the average return of the stocks the analyst covers over the next 12 months. The price target of $16 suggests that the analyst sees significant upside potential in the stock. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.